Dilaudid (Hydromorphone HCl) Patent Expiration, LOE Window & CMS Spending

Dilaudid (Hydromorphone HCl) by Fresenius Kabi: FDA Orange Book LOE 2034-03-12, 6 AB generics, $399K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayN019034 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-03-12
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$399K
2024 Medicare Part D Spend$350K
2024 Medicaid Spend$49K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.